A detailed history of Black Rock Inc. transactions in Maxcyte, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 8,142,364 shares of MXCT stock, worth $28.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,142,364
Previous 7,229,573 12.63%
Holding current value
$28.9 Million
Previous $30.3 Million 5.37%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.63 - $5.0 $3.31 Million - $4.56 Million
912,791 Added 12.63%
8,142,364 $31.9 Million
Q1 2024

May 10, 2024

SELL
$3.94 - $5.38 $440,543 - $601,553
-111,813 Reduced 1.52%
7,229,573 $30.3 Million
Q4 2023

Feb 13, 2024

BUY
$2.6 - $5.24 $1.18 Million - $2.38 Million
453,390 Added 6.58%
7,341,386 $34.5 Million
Q3 2023

Nov 13, 2023

SELL
$3.02 - $5.1 $96,905 - $163,648
-32,088 Reduced 0.46%
6,887,996 $21.5 Million
Q2 2023

Aug 11, 2023

SELL
$3.69 - $5.35 $371,129 - $538,086
-100,577 Reduced 1.43%
6,920,084 $31.8 Million
Q1 2023

May 12, 2023

BUY
$4.03 - $5.89 $828,483 - $1.21 Million
205,579 Added 3.02%
7,020,661 $34.8 Million
Q4 2022

Feb 13, 2023

BUY
$4.92 - $7.4 $1.81 Million - $2.72 Million
367,139 Added 5.69%
6,815,082 $37.2 Million
Q3 2022

Nov 14, 2022

BUY
$4.52 - $6.51 $3.55 Million - $5.11 Million
784,524 Added 13.85%
6,447,943 $41.9 Million
Q2 2022

Aug 12, 2022

BUY
$3.59 - $6.81 $788,299 - $1.5 Million
219,582 Added 4.03%
5,663,419 $26.8 Million
Q1 2022

May 12, 2022

BUY
$5.26 - $10.84 $1.21 Million - $2.49 Million
229,373 Added 4.4%
5,443,837 $38.1 Million
Q4 2021

Feb 10, 2022

BUY
$8.87 - $12.94 $40.2 Million - $58.7 Million
4,535,552 Added 668.06%
5,214,464 $53.1 Million
Q3 2021

Nov 09, 2021

BUY
$12.21 - $17.2 $8.29 Million - $11.7 Million
678,912 New
678,912 $8.29 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $361M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.